BioWorld

Jan. 9, 2004

View Archived Issues

Opportunistic Axonyx Raises $50M Through Public Market

Months after raising $25 million in a private placement, Axonyx Inc. is at it again. But this time, Axonyx has set its sights higher, looking to bring in $50 million. (BioWorld Today) Read More

Novacea Series C Gets $35M To Push Cancer Compounds

Read More

Myogen Begins Enrollment For Ambrisentan Phase III Studies

Read More

Esperion Gets $32.2M From Settlement With Stockholder

Read More

Keryx Acquiring Three Phase II Drugs In 'Success-Based' Buyout

Read More

With 'Hybrid' Business Model, Infinity Signs Amgen To Deal

Read More

ImmunoGen Moving Forward Alone With Cancer Products

Read More

Other News To Note

Read More